论文部分内容阅读
作者使用BC_(369)这种复合生物物质,对多种小鼠的移植性肿瘤,进行了抗肿瘤作用和动物毒理学的试验研究,证实对肿瘤具有抑制生长和杀伤作用,对机体无明显的毒副作用。一年多来,作者采用BC_(369)制剂试治25例Ⅲ期原发性肝癌,从临床资料分析表明,有一定的治疗效果。完全缓解(CR)2例,部分缓解(PR)10例,总缓解率(CR+PR率)48.0％。随访20例,平均生存期10~(1/2)个月,中位生存期10个月,治后半年生存率68.5％,治后一年生存率36.85％。结果提示新型生物抗癌制剂BC_(369)能够延长晚期肝癌病人的生存时间和提高生存质量。
The authors used BC_(369), a complex biological substance, to conduct experimental studies on the anti-tumor effect and animal toxicology of transplanted tumors in a variety of mice, confirming that the tumor has inhibiting growth and killing effects, and has no obvious effect on the body. toxic side effect. For more than one year, the authors used BC_(369) preparations to test 25 cases of stage III primary liver cancer. Analysis of clinical data showed that there are certain therapeutic effects. Complete remission (CR) in 2 cases, partial remission (PR) in 10 cases, total remission rate (CR+PR rate) 48.0%. Followed up 20 patients, the average survival time was 10 to (1/2) months, the median survival time was 10 months, the survival rate was 68.5% after treatment for six months, and the survival rate was 36.85% after treatment. The results suggest that the novel biological anticancer agent BC_(369) can prolong the survival time and improve the quality of life of advanced liver cancer patients.